CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Increasing number of the transplant procedure
4.1.2. Growing burden of infectious diseases
4.1.3. Increasing public-private funding for target research activities
4.1.4. Technological advancements in the field of transplant diagnostics
4.2. Market Restraints & Challenges
4.2.1. High procedural cost of NGS and PCR-based diagnostic assays
4.2.2. Procedural and technical limitations associated with donor-recipient screening
4.2.3. The significant gap between the demand and supply of donor organs required annually
4.2.4. Limited reimbursements for target procedures
4.3. Market Opportunities
4.3.1. Increasing adoption of cross-matching and chimerism testing during pre- & post
Transplantation
4.3.2. Growing public awareness about organ donation and transplantation across emerging countries
CHAPTER 5. GLOBAL TRANSPLANT DIAGNOSTICS MARKET – BY PRODUCT
AND SERVICES
5.1. Instruments
5.2. Software and Services
5.3. Reagents and Consumables
CHAPTER 6. GLOBAL TRANSPLANT DIAGNOSTICS MARKET – BY
TECHNOLOGY
6.1. Molecular Essays
6.1.1. PCR-Based Molecular Assays
6.1.1.1. Real-Time PCR
6.1.1.2. Sequence-Specific Oligonucleotide-PCR
6.1.1.3. Sequence-Specific Primer-PCR
6.1.1.4. Others
6.1.2. Sequencing-Based Molecular Assays
6.1.2.1. Sanger Sequencing
6.1.2.2. Next-Generation Sequencing
6.1.2.3. Others
6.2. Non-Molecular Assays
CHAPTER 7. GLOBAL TRANSPLANT DIAGNOSTICS MARKET – BY TYPE OF
SCREENING
7.1. Pre-transplant Screening
7.2. Post-transplant screening
CHAPTER 8. GLOBAL TRANSPLANT DIAGNOSTICS MARKET – BY
TRANSPLANT TYPE
8.1. Solid Organ Transplantation
8.1.1. Kidney Transplantation
8.1.2. Pancreas Transplantation
8.1.3. Lung Transplantation
8.1.4. Heart Transplantation
8.1.5. Liver Transplantation
8.1.6. Other Organ Transplantations
8.2. Stem Cell Transplantation
8.3. Soft Tissue Transplantation
CHAPTER 9. GLOBAL TRANSPLANT DIAGNOSTICS MARKET – BY
APPLICATION
9.1. Diagnostic Applications
9.1.1. Pre-Transplantation Diagnostics
9.1.1.1. Infectious Disease Testing
9.1.1.2. Histocompatibility Testing
9.1.1.3. Blood Profiling
9.1.2. Post-Transplantation Diagnostics
9.2. Research Applications
CHAPTER 10. GLOBAL TRANSPLANT DIAGNOSTICS MARKET – BY END-USER
10.1. Hospitals & Transplant Centers
10.2. Independent Reference Laboratories
10.3. Academic Institute & Research Laboratories
CHAPTER 11. GLOBAL TRANSPLANT DIAGNOSTICS MARKET - BY
GEOGRAPHY
11.1. Introduction
11.2. North America
11.2.1. U.S.
11.2.2. Canada
11.2.3. Mexico
11.2.4. Costa Rica
11.3. South America
11.3.1. Brazil
11.3.2. Argentina
11.3.3. Chile
11.3.4. Columbia
11.3.5. Others
11.4. Europe
11.4.1. U.K.
11.4.2. Germany
11.4.3. France
11.4.4. Italy
11.4.5. Spain
11.4.6. Russia
11.4.7. Netherlands
11.4.8. Switzerland
11.4.9. Poland
11.4.10. Others
11.5. APAC
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. South Korea
11.5.5. Australia & New Zealand
11.5.6. Malaysia
11.5.7. Singapore
11.5.8. Others
11.6. Middle East & Africa
11.6.1. UAE
11.6.2. Saudi Arabia
11.6.3. Iran
11.6.4. Iraq
11.6.5. Qatar
11.6.6. South Africa
11.6.7. Algeria
11.6.8. Morocco
11.6.9. Nigeria
11.6.10. Egypt
11.6.11. Others
CHAPTER 12. GLOBAL TRANSPLANT DIAGNOSTICS MARKET - COMPANY
PROFILES
12.1. Becton, Dickinson and Company
12.2. Caredx Inc.
12.3. Biomérieux SA
12.4. Bio-Rad Laboratories
12.5. Gendx
12.6. F. Hoffman-La Roche Limited
12.7. Biofortuna Ltd.
12.8. Illumina, Inc.
12.9. Hologic, Inc.
12.10. Immucor, Inc
12.11. Merck KGaA
12.12. Luminex Corporation
12.13. Thermo Fisher Scientific
12.14. Qiagen N.V.
12.15. Omixon HLA
CHAPTER 13. GLOBAL TRANSPLANT DIAGNOSTICS MARKET - COMPETITIVE
LANDSCAPE
13.1. Market Share Analysis
13.2. Strategies adopted by top companies
13.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 14. MARKET INSIGHTS
14.1. Industry Experts Insights
14.2. Analysts Opinions
14.3. Investment Opportunities
CHAPTER 15. APPENDIX
15.1. List of Tables
15.2. List of Figures
